January 22, 2018 Bio/Pharma/CRO M&A, Partnerships Product Launch

Clover Biopharmaceuticals selects GE’s FlexFactory biomanufacturing platform for its new production facility in China

Chalfont St Giles, UK and Changxing, Zhejiang, China – 23 January 2018 — Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, has chosen GE Healthcare’s FlexFactory, a biomanufacturing platform based on single-use technologies, for its new facility located in Changxing, Zhejiang in China. The new facility will mainly be used... Read more

January 22, 2018 Bio/Pharma/CRO M&A, Partnerships Product Launch

Clover Biopharmaceuticals selects GE’s FlexFactory biomanufacturing platform for its new production facility in China

The new facility will support a robust pipeline of biopharmaceuticals, including a biosimilar to Enbrel® for the treatment of rheumatoid arthritisChalfont St Giles, UK and Changxing, Zhejiang, China – 23 January 2018 – Clover Biopharmaceuticals, a biotechnology company focused on developing novel https://www.genewsroom.com/press-releases/clover-biopharmaceuticals-selects-ges-flexfactory-biomanufacturing-platform-its-new Read more

January 19, 2018 Atomic Spectroscopy Bio/Pharma/CRO Clinical Research/Diagn.

First patient enrolled into phase I/II clinical trial of NY-ESO-1・siTCR　gene therapy against synovial sarcoma in Japan

2018 2018/01/19 First patient enrolled into phase I/II clinical trial of NY-ESO-1・siTCR　gene therapy against synovial sarcoma in Japan Kusatsu/Shiga, Japan — January 17, 2018 — Takara Bio Inc. (Takara Bio), today announced that the first patient with synovial sarcoma has been enrolled into NY-ESO-1・siTCR gene therapy (TBI-1301) phase I/II clinical trial in Japan on January... Read more

January 8, 2018 Bio/Pharma/CRO Product Launch

Unchained Labs gives Lunatic a boost, nails high-end biologic quant!

January 8, 2018 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, amped up the protein quant range on Lunatic today, making measurements of up to 250 mg/mL IgG a cinch for biologics researchers. High-concentration biologics don’t have to be administered as often, plus patients... Read more

January 4, 2018 Acad, Gov/Utilities Bio/Pharma/CRO Clinical Research/Diagn. Environ, Ag./Food & Bev Life Science Tools M&A, Partnerships

Illumina and KingMed Diagnostics Partner to Develop Next-Generation Sequencing Technology for Chinese FDA Approval

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) and KingMed Diagnostics (SSE: 603882.SS) today announced an agreement to jointly develop novel oncology and hereditary disease testing applications utilizing Illumina’s next-generation sequencing (NGS) technology. The collaboration is a significant step toward China Food and Drug Administration (CFDA) review and approval, and serves as a starting point to deliver... Read more

December 12, 2017 Bio/Pharma/CRO PR/Corporate

Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia

Basel, 12 December 2017 Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia This chemotherapy-free combination showed improvements across multiple efficacy measures compared to bendamustine plus MabThera/Rituxan in the pivotal MURANO trial... Read more

December 12, 2017 Bio/Pharma/CRO PR/Corporate

Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia

Basel, 12 December 2017 Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia This chemotherapy-free combination showed improvements across multiple efficacy measures compared to bendamustine plus MabThera/Rituxan in the pivotal MURANO trial... Read more

December 11, 2017 Bio/Pharma/CRO PR/Corporate

Phase III IMmotion151 study showed Roche’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer

Basel, 11 December 2017 Phase III IMmotion151 study showed Roche’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer Tecentriq and Avastin showed improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1 Data will... Read more

December 11, 2017 Bio/Pharma/CRO PR/Corporate

Phase III IMmotion151 study showed Roche’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer

Basel, 11 December 2017 Phase III IMmotion151 study showed Roche’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer Tecentriq and Avastin showed improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1 Data will... Read more

December 10, 2017 Bio/Pharma/CRO PR/Corporate

Phase II data showed Roche’s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone in previously treated aggressive lymphoma

Basel, 10 December 2017 Phase II data showed Roche’s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone in previously treated aggressive lymphoma Polatuzumab vedotin combination demonstrated improvements across multiple efficacy measures compared to BR alone in relapsed or refractory diffuse large B-cell lymphoma These data led to... Read more